Cerus Q2 revenue $37.8M (+41% YoY); raises FY product revenue guidance to $118-122M

CERUS CORP

Total revenue $37.8M (+41% YoY); product revenue $31.5M (+46%) led by 128% North America platelet growth.
FY2021 product revenue guidance raised to $118-122M from $110-114M, representing 28-33% growth over 2020.
Net loss $15.4M ($0.09/sh) vs $14.9M ($0.09) in Q2 2020; cash and investments $122.8M at quarter end.
Submitted PMA supplement for 7-day INTERCEPT platelet storage; final CE Mark module for INTERCEPT red cells.
CMS granted NTAP for INTERCEPT Fibrinogen Complex; initial hospital contracts signed; LifeSouth collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.